2 unknown. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Unknown 2 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Imatinib - Chronic Myeloid Leukemia | Phase 4 | Unknown | Cttq | 90 | 2015-02-01 | 2014-12-15 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)
Bone Marrow Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Dasatinib (1) · Imatinib Mesylate (1)
Cttq (1) · Shenzhen Second People's Hospital (1)
China (1)